ZEFIT offers Onco-FIT, a preclinical testing services using zebrafish-based in vivo models for anticancer drug discovery. Zefit provides a cell-derived xenograft model, allowing real-time visualization of tumor growth and metastasis in zebrafish larvae. This allows for rapid assessment of anticancer compounds’ efficacy from anticancer compounds.
Advertisements
Features of Onco-FIT:
- Zebrafish embryos offer rapid drug screening, real-time visualization, and efficient metastasis evaluation through tumor inhibition and metastasis data within 5 days, facilitated by angiogenesis and tumor cell migration analysis.
- Fluorescence microscopy is used to quantify the tumor inhibition effects of drug candidates in transparent embryos, enabling the assessment of tumor proliferation and suppression.
- Zebrafish embryos enable rapid tumor cell assessment and real-time observation of cell migration patterns.
- Accelerating data acquisition from timer cell metastasis via the vascular system rapid assessment of tumor cell dissemination via the vascular system.
- High-throughput screening for drug development often uses small molecule screening for lead compound selection, supporting various solubilities and compatibilities with various vehicle systems and targeted therapies.
- Macromolecule screening involves specialized screening for various drugs, including ADC, antibodies, biologics, nanoparticles, and gene therapy vectors, allowing stable drug concentrations and IV-based administration.
- The platform offers customizable protocols based on specific drug types and research needs, becoming a suitable option. It also supports combination treatments and sequential drug testing, becoming a suitable option for preclinical trials and industrial applications.
If you are looking for an anticancer drug discovery platform, you can find them at ZEFIT.
Click here if you are interested in ZEFIT Services.
View more: A Revolutionary In Vivo Cancer Drug Testing Platform for Early-Stage Drug Development
